Home » Stocks » BPTS

Biophytis S.A. (BPTS)

Stock Price: $14.42 USD -0.18 (-1.26%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 162.16M
Revenue (ttm) n/a
Net Income (ttm) -19.10M
Shares Out 11.28M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $14.42
Previous Close $14.60
Change ($) -0.18
Change (%) -1.26%
Day's Open 14.60
Day's Range 14.01 - 14.42
Day's Volume 730
52-Week Range 14.01 - 18.50


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology compan...

GlobeNewsWire - 2 weeks ago

PARIS and CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqGS: BPTS; Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of ...

GlobeNewsWire - 2 weeks ago

PARIS and CAMBRIDGE, Mass., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Biophytis (NasdaqCM: BPTS; Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company fo...

GlobeNewswire - 3 weeks ago

Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage...

NASDAQ - 1 month ago

Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, filed on Tuesday with the SEC to raise up to $15 million in an initial public...

SEC - 1 month ago

Biophytis S.A. has filed to go public with an IPO on the NASDAQ.

About BPTS

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in deve... [Read more...]

IPO Date
Feb 10, 2021
Stanislas Veillet
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements